eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint blockade (ICB) targeting PD-L1/PD-1 pathway shows promise in cancer therapy but faces efficacy limitations.
• Understanding PD-L1 regulation is crucial for improving cancer immunotherapy.
• The role of eukaryotic elongation factor 2 kinase (eEF2K) in the tumor immune microenvironment (TIME) is largely unknown.

Purpose of the Study:

• To investigate the association between eEF2K expression and anti-PD-1 immunotherapy efficacy in melanoma patients.
• To elucidate the molecular mechanism by which eEF2K regulates PD-L1 expression.
• To evaluate the therapeutic potential of combining eEF2K inhibition with anti-PD-1 treatment.

Main Methods:

• Analysis of a melanoma patient cohort treated with anti-PD-1 therapy.
• Immunoprecipitation-mass spectrometry and in vitro assays to study eEF2K's role in PD-L1 regulation.
• In vivo studies using a mouse melanoma model to assess eEF2K's impact on tumor growth, T cell activity, and combination therapy efficacy.

Main Results:

• High eEF2K expression correlated with better response and survival in anti-PD-1 treated melanoma patients.
• eEF2K positively regulates PD-L1 expression by phosphorylating and inactivating GSK3β, leading to PD-L1 stabilization and immune evasion.
• Knockdown of eEF2K decreased PD-L1, enhanced CD8+ T cell activity, and reduced tumor growth in mice.
• Combined eEF2K inhibition and anti-PD-1 therapy showed enhanced efficacy in a melanoma mouse model.

Conclusions:

• eEF2K may serve as a predictive biomarker for anti-PD-1 therapy response and prognosis.
• eEF2K plays a critical role in regulating the TIME by controlling PD-L1 expression.
• Inhibiting eEF2K in combination with ICB represents a promising therapeutic strategy for melanoma.